Changes in Relevant for UDS 2025

Note: These changes were made based on the PAL released October 31, 2024. Additional updates may occur when HRSA releases the 2025 UDS Manual. This page was last updated on July 28, 2025.

Table 6A: Selected Services Rendered

New line additions

  • 26c2. Tobacco Use Cessation Pharmacotherapies: The number of visits/patients where patients received tobacco cessation pharmacotherapies as an intervention.
  • 26c3. Medications for Opioid Use Disorder (MOUD): The number of visits/patients where patients received medication based intervention for Opioid Use Disorder.
  • 26f. Alzheimer’s Disease and Related Dementias (ADRD) Screening: The number of visits/patients where patients received ADRD screenings.

New counting approach

We introduced a new way to count certain lines, using Data Elements instead of Visit Billing Codes. This allows more accurate reporting for services that aren’t typically billed in the EHR or are performed by external labs or third party providers. This approach is currently limited to the rows listed below; we may extend this pattern to additional lines in the future. Read more about Counting Selected Services in Table 6A.

     
Line Service Category Data Element
21 HIV Test HIV Screening Tests
21a Hepatitis B test Hep B Antigen Labs
21b Hepatitis C test Hep C Tests
22 Mammogram Mammograms
26c Smoke and tobacco use cessation counseling Tobacco Use Cessation Treatments
Limited to rows with treatment_category = ‘counseling’
26c2 Smoke and tobacco use cessation pharmacotherapy Tobacco Use Cessation Treatments
Limited to rows with treatment_category = ‘pharmacotherapy’
26c3 Medications for opioid use disorder Opioid Use Disorder Medication Administrations
26a Childhood lead test screening (9 to 72 months) Lead Blood Tests
26f Alzheimer’s disease and related dementias (ADRD) screenings Cognitive Assessment Screens

Table 6B: New Measure

  • Initiation and Engagement of Substance Use Disorder (SUD) Treatment (CMS137v13)

    • Line 23a: % of patients initiating treatment within 14 days of a new SUD diagnosis.

    • Line 23b: % engaging in treatment within 34 days.

Table 6B: Changes to Quality Measures

eCQM Alignment for Tables 6B and 7

  • 13 Clinical Quality Measures were updated to latest CMS versions (e.g., CMS117v13 for childhood immunizations, CMS122v13 for diabetes).

  • HIV Linkage to Care (UDS 2025 Table 6B) was updated to require at least one qualifying encounter during the measurement period. Last year’s measure required at least one eligible countable visit during the measurement period or prior year. (Note: this change wasn’t announced in the PAL but was discovered in the UDS 2025 manual on page 112.)

Renamed quality measures

  • “Diabetes: Glycemic Status Assessment Less Than or Equal to 9%”

New data elements

  • Glucose Management Indicator (GMI) Tests. Introduced May 2025. This data element is necessary to accommodate the changes to “Diabetes: Glycemic Status Assessment Less Than or Equal to 9%”, which now includes GMI tests from continuous glucose monitors as a glycemic status assessment on top of hemoglobin A1c tests.
  • Substance Use Cases. Introduced January 2025. This data element is necessary for defining substance use episodes in our new Initiation and Engagement of Substance Use Disorder (SUD) Treatment measure.
  • Substance Use Treatments. Introduced January 2025. This data element is necessary for defining initiation of treatment and treatment engagement in our new Initiation and Engagement of Substance Use Disorder (SUD) Treatment measure.

New qualifying visit views for all measures

  • All UDS Measures with eCQM specifications for defining a “Qualifying Encounter” using value sets now have a specific view in the rdm schema. The views output the visits.id, patient_id, visit_date, and qualifying_code from the value sets used. The universe query in the measure SQL now use the views to filter down to only patients with qualifying visits.